SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
May 17, 2018 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel...
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
May 15, 2018 08:10 ET
|
Novan, Inc.
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
Novan Advances Organization and Strengthens Leadership Team
April 12, 2018 07:05 ET
|
Novan, Inc.
CEO Role No Longer “Interim”Clinical Operations Role Established Finance Team Positioned for the Future MORRISVILLE, N.C., April 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or...
Novan Announces Corporate Update Conference Call and Webcast
March 29, 2018 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 29, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Thursday, April 12, at 8:30...
Dr. Eugene Sun Appointed to Novan Board of Directors
February 21, 2018 08:00 ET
|
Novan, Inc.
Complements existing Board expertise as 30-year clinician, drug developer and former biopharmaceutical CEOWill provide expert perspective on the clinical application of the underlying nitric oxide...
Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
February 13, 2018 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term...
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
January 25, 2018 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...
Novan Announces Closing of Offering of Common Stock and Warrants
January 11, 2018 09:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offering. ...
Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
January 11, 2018 09:10 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based...
Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants
January 05, 2018 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's underwritten offering of 10 million shares of...